Shubham Pant, Professor of Gastrointestinal Medical Oncology and Investigational Cancer Therapeutics at MD Anderson Cancer Center, shared an article He and His collogues co-authored on Nature Communications, on LinkedIn, adding:
“Pleased to share the recent publication in Nature Communications:
‘Engineered exosomes with KRAS G12D specific siRNA in pancreatic cancer: a phase I study with immunological correlates.’
This work was a truly collaborative effort between the Raghu Kalluri lab and our clinical team, focused on one of the most pressing challenges in oncology – KRAS G12D – mutant pancreatic cancer. When we launched this trial, there were almost no therapeutic studies in this space.
The most difficult – and humbling – part of this journey was witnessing the tremendous need, underscored by the number of patients and caregivers who reached out for trial participation.
I remain hopeful that the advances being made with KRAS-targeted therapies will soon translate into approved treatments, providing patients with meaningful new options.
There is one person who deserves special recognition – Dr. Gauri Varadhachary, who played a key role in designing this trial. Gauri was an extraordinary physician, mentor, and colleague – selfless, kind, and full of grace. She embodied compassion and excellence in everything she did.
Gauri, we miss your presence and light…”
Title: Engineered exosomes with KrasG12D specific siRNA in pancreatic cancer: a phase I study with immunological correlates
Authors: Valerie S. Kalluri, Brandon G. Smaglo, Krishnan K. Mahadevan, Michelle L. Kirtley, Kathleen M. McAndrews, Mayela Mendt, Sujuan Yang, Ana S. Maldonado, Hikaru Sugimoto, Maria E. Salvatierra, Luisa M. Solis Soto, Cara Haymaker, Rick Finch, Mihai Gagea, Adam C. Fluty, Steven J. Ludtke, J. Jack Lee, Abhinav K. Jain, Gauri Varadhachary, Rachna T. Shroff, Anirban Maitra, Elizabeth Shpall, Shubham Pant and Raghu Kalluri
Read the full article on Nature Communications.
Read more posts about Pancreatic Cancer on OncoDaily.